1 / 31

Fibrodysplasia ossificans Progressiva (FOP)

Fibrodysplasia ossificans Progressiva (FOP). Samantha He Medical Genetics 12/31/09. A baffling and rare disease. John Ferke of Saint Bartholomew’s Hospital, 1741:

christina-stathis
Download Presentation

Fibrodysplasia ossificans Progressiva (FOP)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fibrodysplasia ossificans Progressiva (FOP) Samantha He Medical Genetics 12/31/09

  2. A baffling and rare disease John Ferke of Saint Bartholomew’s Hospital, 1741: ‘ …They arise from all over the vertebrae of the neck and reach down to the sacrum; they likewise arise from every rib of his body, and joining together in all parts of his back, as the ramifications of corals do, they make as it were, a fixed bony pair of bodice.’

  3. General overview of FOP • Soft connective tissue that progressively turn into bone • Occurrence: 1 /2,000,000 • Regardless of gender and ethnicity • 700 confirmed cases in the world, 285 known cases in U.S • Misdiagnosis rate around 60%~80% • Cancer • Juvenile Firbromatosis • Median age of survival: 45 years • No cure

  4. (Kaplan et al. 2008)

  5. Genetics of FOP • Discovered in 2006 • Heritable in typical autosomal dominant pattern • Low reproductive fitness • Complete penetrance • Phenotype: Heterotopic Ossificans (HO) • Heterotopic = misplaced • Heterozygous point mutation on Activin Receptor IA (ACVR1) gene • Novel mutations cause atypical FOP

  6. Cytogenic Location • 2q23-q24 (“ACVR1,” n.d., Where is ACVR1 located, figure 1)

  7. (Feldman et al. 2000)

  8. ACVR1 • Also known as Activin receptor-like kinase-2 (ALK2) • Gene • Codes for Activin receptor type 1 protein • ACVR1 protein function • Controls and regulates growth of bones, muscles and ossification recruit and phosphorylate signaling molecules (Smad) • Signaled by bone morphogenic protein (BMP) • Effects growth and differentiation of cells • Mutation: • Ligand dependent over responsiveness • Ligand independent leakiness

  9. How AVCR1 works (Kaplan et al. 2008)

  10. AVCR1 schematic diagram • Typical mutation on AVCR1 • Missense mutation at codon 206 of GS region (Shore et al. 2008)

  11. ACVR1 schematic diagram • Atypical mutations noted in FOP patients (Petrie et al. 2009) R = Arginine I = Isoleucine G= Glycine H= Histidine E=Glutamic Acid

  12. Histological insight on FOP • Transgenic mice enables researchers to study progressive growth of heterotrophic bone (Kan et al. 2004)

  13. Phase I • Local proliferation of fibroblast-like near muscle cells (Kan et al. 2004)

  14. Phase II • de novo blood vessels in connective tissue near dense fibromatic region (Kan et al. 2004)

  15. Phase III (Kan et al. 2004) • Inner cells of new growth shows chondrocyte like morphology

  16. Phase IV (Kan et al. 2004) • Multifocal, central, and hypertrophic chondrocytes surrounded by high proliferating fibroblast like cells

  17. Clinical Features of FOP • Malformed great toes in newborns • HO mimics embryonic development • Axial  appendicular • Crainal  caudual • Proximal  distal • Episodic HO • flare ups of tumor like swellings, soft tissue lesions transformed into bone • Skeletal muscle, tendons, joints, soft connective tissue, aponeuroses, fascia, ligaments • Smooth muscle and cardiac muscles are spared

  18. Clinical Features of FOP • Injury induced HO • Due to inflammatory response of cell proliferation • Complications • Thoracic insufficiency syndrome • Heart failure • Severe weight loss

  19. Clinical data (Lee. et al 2009)

  20. Big toe malformation

  21. Treatment • Lifestyle changes • Injury prevention • Caution involving medical procedures • Surgery is to be avoided • Intramuscular injections (includes local anesthesia) • Drugs • Anti-inflammatory • Cortical steroids  only for major joints, jaws/mandible • Non steroidal anti inflammatory drugs • Anti-angiogenic • Aminobiphosphates – inhibits mineralization • Muscle relaxtant

  22. Future Treatment? • ACVR1/ALK2 signal transduction inhibitor • Monoclonal antibody against ACVR1/ALK2 • Blocks receptor at cell surface (Kaplan et al. 2007)

  23. LDN-193189 inhibits activation of BMP signaling effectors (Smads) (Yu et al. 2008)

  24. FOP pregnancy • High risk to both mother and child • Complications for mother • Flare-ups during pregnancy and management • Breathing problems • Childbirth complications • Complications for child • 50% chance of inheriting FOP • Fetal distress because of poor blood supply • Premature

  25. Differential diagnosis • Progressive Osseous Heteroplasia (POH) • Genetic condition of progressive ossification • Differs from FOP • Does not have flare ups • Bones grows in skin and fat tissue • Bone growth spreads like a web • from skin down to subcutaneous tissue and muscles • Clinical sign: rice grain like particles under the skin • Differentiated from FOP during research • Mutation is on a different gene

  26. Other mysteries of FOP • Variable age of onset • Generally within 1-5th year • Other cases: teens-late teens, adults • Episodic HO that’s unpredictable • HO can stop for as long as 9 years or more • Triggers of flare ups • Some major injury will not trigger HO, but sometimes even walking will trigger HO

  27. End Quote • “Doctors work in the light, but researchers work in the dark. As researchers, our job is to find the switch that can light up people’s lives for generations to come”

  28. References Kan, L.X., Hu, M., Gomes, W.A., Kessler, J.A. (2004) Transgenic mice overexpressing BMP4 Develop Fibrodysplasia Ossificans Progressiva (FOP) Like Phenotype. Am J Pathol 165 (4): 1107-1115 Kaplan, F.S., Le Merrer, M., Glaser, D.L., Pignolo, R.J., Goldsby, R.E., et al. (2008) Fibrodysplasia Ossificans Progressiva. Best Pract Res Clin Rheumatol 22(1): 191-205. Kaplan, F.S., Xu, M.Q., Glaser, D.L., Collins, F., Connor, M., et al. (2008) Early Diagnosis of Fibrodysplasia Ossificans Progressiva. Pediatrics 121 (5): 1295-1300 Lee, D.Y., Cho, T.J., Lee, H.R., Park, M.S., Chung, C.Y., Choi, I.H. (2009) ACVR1 Gene Mutation in Sporadic Korean Patients with Fibrodysplasia Ossificans Progressiva. J Korean Med Sci 24: 433-7. doi: 10.3346/jkms.2009.24.3.433

  29. References Petrie, K.A., Lee, W.H., Bullock, A.N., Pointon, J.J., Smith, R., et al. (2009) Novel Mutations in ACVR1 Results in Atypical Features in Two Fibrodysplasia Ossificans Progressiva Patients. PLoS ONE 4(3): e5005. doi: 10.1371/journal.phone.005005 Shore, E.M., Kaplan, F.S. (2008) Insights from a Rare Genetic Disorder of Extra-skeletal Bone Formation, Fibrodisplasia Ossificans Progressiva. Bone 43(3): 427-433. doi: 10.1016/j.bone.2008.05.013. Yu, P.B., Deng, D.Y., Lai, C.S., Hong, C.C., Cuny, G.D., et al. (2008) BMP type I receptor inhibition reduces heterotopic ossification . Nat Med 14: 1363-1369. ACVR1 . (December, 21, 2009). Retrieved December 29, 2009, from Genetics Home Reference. Website: http://ghr.nlm.nih.gov/gene=acvr1

More Related